EVMN
Evommune, Inc.
$23.51
+5.52%
$802.5M
No data for this timeframe.
Vol
Market Cap$802.5M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders5 funds
Inst. Value$10.2M
Inst. Activity5 buys / 0 sells
SEC Reports5
Recent Activity
Apr 27, 2026
SEC
Evommune's S-1 registration has become effective, allowing for the resale of 4.49 million shares by existing shareholder
EFFECT — Impact 4/10
Apr 21, 2026
SEC
Evommune, Inc. filed a DEFA14A proxy statement for its 2026 annual meeting, where shareholders will vote on the election
DEFA14A — Impact 3/10
Apr 17, 2026
SEC
This S-1 filing is a resale registration statement for 4.49 million shares of Evommune (EVMN) being sold by existing inv
S-1 — Impact 4/10
Apr 16, 2026
Insider
Carver Kyle sold 98,946 shares
Chief Financial Officer @ $0.00 ($0.00)
Apr 16, 2026
Insider
Pena Luis C. sold 291,420 shares
President & CEO @ $0.00 ($0.00)
Apr 16, 2026
Insider
Moss Gregory S. sold 115,279 shares
Chief Business & Legal Officer @ $0.00 ($0.00)
Inst.
VANGUARD GROUP INC — NEW
502,574 shares ($8.6M)
Inst.
CHARLES SCHWAB INVESTMENT MANAGEMENT — NEW
62,704 shares ($1.1M)
Price Targets
$52.25
+122.2% upside
Strong Buy
Current $23.51
Low $50.00
Median $52.00
High $55.00
8 analysts
$50.00
$55.00
Analyst Ratings
6Strong Buy
9Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 11, 2026 | Morgan Stanley | MAINTAIN | Overweight → Overweight |
| Apr 10, 2026 | RBC Capital | REITERATE | Outperform → Outperform |
| Mar 18, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 18, 2026 | Clear Street | INITIATE | Buy |
| Feb 10, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.68 ▲ +1.6% | $-0.76 — $-0.61 | 8 | |
| Next Q | $-0.69 ▼ -5.1% | $-0.90 — $-0.18 | 91% YoY | 8 |
| Current FY | $-2.78 ▲ +13.5% | $-3.30 — $-2.09 | 75% YoY | 8 |
| Next FY | $-3.33 ▲ +1.1% | $-4.83 — $-2.48 | -20% YoY | 8 |
Latest Reports
NEUTRAL
EFFECT
4/10
Evommune's S-1 registration has become effective, allowing for the resale of 4.49 million shares by existing shareholder
Apr 27, 2026
NEUTRAL
DEFA14A
3/10
Evommune, Inc. filed a DEFA14A proxy statement for its 2026 annual meeting, where shareholders will vote on the election
Apr 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $8.6M | NEW |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $1.1M | NEW |
| TWO SIGMA INVESTMENTS, LP | $365.1K | NEW |
| MORGAN STANLEY | $142.9K | NEW |
| BANK OF AMERICA CORP | $50.3K | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 16, 2026 | Carver Kyle | A | $0.00 |
| Apr 16, 2026 | Pena Luis | A | $0.00 |
| Apr 16, 2026 | Moss Gregory | A | $0.00 |
| Apr 16, 2026 | Bauer Eugene | A | $0.00 |
| Apr 16, 2026 | Drew Janice | A | $0.00 |
5 institutional holders with $10.2M total value (597,885 shares) as of 2025-Q4. Top holders: VANGUARD, CHARLES, TWO. Net buying activity: 5 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 502,574 | $8.6M | 84.1% | NEW |
| 2 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 62,704 | $1.1M | 10.5% | NEW |
| 3 | TWO SIGMA INVESTMENTS, LP | 21,324 | $365.1K | 3.6% | NEW |
| 4 | MORGAN STANLEY | 8,346 | $142.9K | 1.4% | NEW |
| 5 | BANK OF AMERICA CORP /DE/ | 2,937 | $50.3K | 0.5% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | NEW | — | 502,574 | — | $8.6M | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 62,704 | — | $1.1M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 21,324 | — | $365.1K | 2025-Q4 |
| MORGAN STANLEY | NEW | — | 8,346 | — | $142.9K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEW | — | 2,937 | — | $50.3K | 2025-Q4 |
7 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 16, 2026 | Carver Kyle | Chief Financial Officer | A | 98,946 | $0.00 | $0.00 |
| Apr 16, 2026 | Pena Luis C. | President & CEO | A | 291,420 | $0.00 | $0.00 |
| Apr 16, 2026 | Moss Gregory S. | Chief Business & Legal Officer | A | 115,279 | $0.00 | $0.00 |
| Apr 16, 2026 | Bauer Eugene | Chief Medical Officer | A | 51,117 | $0.00 | $0.00 |
| Apr 16, 2026 | Drew Janice Suzann | Chief of Dev. Operations | A | 73,892 | $0.00 | $0.00 |
| Apr 16, 2026 | Patel Jeegar Pravinkumar | Chief Scientific Officer | A | 69,315 | $0.00 | $0.00 |
| Feb 17, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | A | 35,868 | $27.88 | $1000.0K |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 4.4/10.
NEUTRAL
EFFECT
4/10
Evommune's S-1 registration has become effective, allowing for the resale of 4.49 million shares by
Apr 27, 2026
NEUTRAL
DEFA14A
3/10
Evommune, Inc. filed a DEFA14A proxy statement for its 2026 annual meeting, where shareholders will
Apr 21, 2026
NEUTRAL
S-1
4/10
This S-1 filing is a resale registration statement for 4.49 million shares of Evommune (EVMN) being
Apr 17, 2026
NEUTRAL
8-K
3/10
Evommune hosted a webcast on April 13, 2026, highlighting its EVO756 program targeting MRGPRX2 for m
Apr 13, 2026
BULLISH
8-K
8/10
Evommune reported positive Phase 2a data for EVO301 in atopic dermatitis and advanced its EVO756 pro
Mar 5, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (94% buy). Based on 16 analysts: 6 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$52.25 mean target
+122.2% upside
Strong Buy (1.20)
$50.00 Low
$55.00 High
| Metric | Value |
|---|---|
| Current Price | $23.51 |
| Target Low | $50.00 |
| Target Mean | $52.25 |
| Target Median | $52.00 |
| Target High | $55.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.20) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.68 | $-0.76 | $-0.61 | — | +1.6% | 1↑ 1↓ | $0.0B | — | 8 |
| Next Q 2026-09-30 |
$-0.69 | $-0.90 | $-0.18 | 91.5% | -5.1% | 2↑ 2↓ | $0.0B | -70.9% | 8 |
| Current FY 2026-12-31 |
$-2.78 | $-3.30 | $-2.09 | 75.3% | +13.5% | 4↑ 1↓ | $0.0B | -48.8% | 8 |
| Next FY 2027-12-31 |
$-3.33 | $-4.83 | $-2.48 | -19.9% | +1.1% | 4↑ 1↓ | $0.0B | -88.4% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.677 | |
| 7d ago | $-0.667 | -0.010 |
| 30d ago | $-0.689 | +0.011 |
| 60d ago | $-0.688 | +0.010 |
| 90d ago | $-0.603 | -0.075 |
10 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 9 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 11, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Apr 10, 2026 | RBC Capital | REITERATE | Outperform | Outperform |
| Mar 18, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 18, 2026 | Clear Street | INITIATE | — | Buy |
| Feb 10, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 22, 2026 | Oppenheimer | INITIATE | — | Outperform |
| Jan 8, 2026 | Raymond James | INITIATE | — | Strong Buy |
| Jan 6, 2026 | HC Wainwright & Co. | INITIATE | — | Buy |
| Dec 1, 2025 | William Blair | INITIATE | — | Outperform |
| Dec 1, 2025 | Cantor Fitzgerald | INITIATE | — | Overweight |
| Dec 1, 2025 | Morgan Stanley | INITIATE | — | Overweight |
| Dec 1, 2025 | Leerink Partners | INITIATE | — | Outperform |
| Dec 1, 2025 | Evercore ISI Group | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 6 | 9 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 6 | 7 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 6 | 7 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 20, 2026
Clinical Trial
A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
Phase Phase 2 — COMPLETED
Mar 24, 2026
short_interest
FTD: EVMN — 77,091 shares ($1.8M) failed to deliver
Settlement: 20260324, Price: $23.45, FTD Value: $1,807,783.95, EVOMMUNE INC COM
Mar 23, 2026
short_interest
FTD: EVMN — 75,985 shares ($1.8M) failed to deliver
Settlement: 20260323, Price: $23.33, FTD Value: $1,772,730.05, EVOMMUNE INC COM
Feb 11, 2026
short_interest
FTD: EVMN — 25,444 shares ($0.7M) failed to deliver
Settlement: 20260211, Price: $29.03, FTD Value: $738,639.32, EVOMMUNE INC COM